CRITICAL OUTCOME T COM NPV(POST REV SPLIT) (NASDAQ:COTQF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Friday.

According to Zacks, “Critical Outcome Technologies Inc. is a biopharmaceutical company which focuses on treatment of cancer. The company’s product consists of COTI-2, a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. Its artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing. Critical Outcome Technologies Inc. is based in London, Canada. “

Separately, ValuEngine cut shares of CRITICAL OUTCOME T COM NPV(POST REV SPLIT) from a “sell” rating to a “strong sell” rating in a research report on Thursday.

CRITICAL OUTCOME T COM NP (NASDAQ:COTQF) traded up 4.4551% on Friday, reaching $0.8511. 500 shares of the company’s stock were exchanged. The firm’s market capitalization is $13.79 million. The firm has a 50-day moving average of $0.25 and a 200-day moving average of $0.22. CRITICAL OUTCOME T COM NP has a 12 month low of $0.83 and a 12 month high of $4.80.

ILLEGAL ACTIVITY NOTICE: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/06/critical-outcome-t-com-npvpost-rev-split-cotqf-rating-lowered-to-sell-at-zacks-investment-research.html.

About CRITICAL OUTCOME T COM NPV(POST REV SPLIT)

Critical Outcome Technologies Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer in Canada. The company’s proprietary artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing.

Get a free copy of the Zacks research report on CRITICAL OUTCOME T COM NPV(POST REV SPLIT) (COTQF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CRITICAL OUTCOME T COM NPV(POST REV SPLIT) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRITICAL OUTCOME T COM NPV(POST REV SPLIT) and related companies with MarketBeat.com's FREE daily email newsletter.